Is Roflumilast-DALIRESP on the market?

Roflumilast Tablets (Roflumilast)-DALIRESP is an oral formulation used to treatchronic obstructive pulmonary disease (COPD; COPD). The drug was first approved by the European Medicines Agency (EMA) in July 2010, and was subsequently approved by the U.S. Food and Drug Administration (FDA) in January 2018, officially entering the market. As a highly selective phosphodiesterase-4 (PDE-4) inhibitor, roflumilast's main mechanism of action is to increase the concentration of intracellular cyclic-3',5'-adenosine monophosphate (cAMP) by inhibiting the activity of PDE-4. This process is believed to effectively reduce the inflammatory response and improve the patient's condition.

In clinical applications, roflumilast is widely used in the treatment of COPD patients, especially those who experience frequent acute exacerbations. Although its exact mechanism of action has not been fully elucidated, studies have shown that roflumilast can significantly alleviate the inflammatory response caused by COPD by reducing the release of pro-inflammatory cytokines. In addition, roflumilast may help improve lung function test results and reduce the incidence of exacerbations.

It is worth noting that roflumilast tablets have also been launched in Hong Kong, China, under the trade nameDaxas (Dikaisu), which is the name of its original research version. The introduction of this drug provides new treatment options for COPD patients, helping them manage their condition and improve their quality of life. With the in-depth understanding of the pathophysiology of COPD, roflumilast, as a new therapeutic drug, has promising clinical application prospects.

However, although roflumilast tablets are already on the market and approved by many countries, doctors still need to carefully evaluate the patient's specific situation when prescribing to ensure the safety and effectiveness of its medication. During use, patients may experience some adverse reactions, so regular monitoring and follow-up are required during treatment to detect and deal with potential problems in a timely manner.

Reference materials:https://en.wikipedia.org/wiki/Roflumilast